JournalsHub
.online
Find My Journal
PV

Paula J. Valentine

AstraZeneca (United Kingdom) GB

5
Publications
1,523
Citations
3
H-Index
2
i10-Index
0
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex . OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
Stephen R. Wedge, Donald Ogilvie, Michael Dukes, Jane Kendrew, Rosemary Chester +14 more
PubMed 2002
802
AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer OA
Stephen R. Wedge, Jane Kendrew, Laurent Hennequin, Paula J. Valentine, Simon T. Barry +19 more
Cancer Research 2005
709
The VEGF receptor tyrosine kinase inhibitor AZD2171 inhibits VEGF signaling, angiogenesis, and tumor growth in vivo
Stephen R. Wedge, Jane Kendrew, Paula J. Valentine, Lyndsey L. Kilburn, Jon Curwen +10 more
Cancer Research 2004
9
Abstract 1372: Cediranib alone and in combination with mechanistically distinct antitumor therapies in vivo
Juliane M. Jürgensmeier, Jane Kendrew, Rajesh Odedra, Armelle Logié, Philippa Wood +8 more
Cancer Research 2010
2
165 AZD2171, a potent VEGF receptor tyrosine kinase inhibitor, combined with mechanistically distinct antitumor therapies in vivo
Stephen R. Wedge, Jane Kendrew, Paula J. Valentine, Sandra R. Brave, S. Barnett +3 more
European Journal of Cancer Supplements 2004
1

Publications

5 total

Abstract 1372: Cediranib alone and in combination with mechanistically distinct antitumor therapies in vivo

Juliane M. Jürgensmeier, Jane Kendrew, Rajesh Odedra, Armelle Logié, Philippa Wood et al. - Cancer Research, 2010
Cited by 2 OpenAlex

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer PDF

Stephen R. Wedge, Jane Kendrew, Laurent Hennequin, Paula J. Valentine, Simon T. Barry et al. - Cancer Research, 2005
Cited by 709 OpenAlex

The VEGF receptor tyrosine kinase inhibitor AZD2171 inhibits VEGF signaling, angiogenesis, and tumor growth in vivo

Stephen R. Wedge, Jane Kendrew, Paula J. Valentine, Lyndsey L. Kilburn, Jon Curwen et al. - Cancer Research, 2004
Cited by 9 OpenAlex

165 AZD2171, a potent VEGF receptor tyrosine kinase inhibitor, combined with mechanistically distinct antitumor therapies in vivo

Stephen R. Wedge, Jane Kendrew, Paula J. Valentine, Sandra R. Brave, S. Barnett et al. - European Journal of Cancer Supplements, 2004
Cited by 1 OpenAlex

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Stephen R. Wedge, Donald Ogilvie, Michael Dukes, Jane Kendrew, Rosemary Chester et al. - PubMed, 2002
Cited by 802 OpenAlex

Research Topics

Angiogenesis and VEGF in Cancer (4) PI3K/AKT/mTOR signaling in cancer (3) Cancer Treatment and Pharmacology (2) Hepatocellular Carcinoma Treatment and Prognosis (1) Sarcoma Diagnosis and Treatment (1)

Frequent Co-Authors

ST
Stephen R. Wedge
5 joint publications
JA
Jane Kendrew
5 joint publications
DO
Donald Ogilvie
4 joint publications
LA
Laurent Hennequin
4 joint publications
JO
Jon Curwen
3 joint publications
GR
Graham H.P. Richmond
3 joint publications

Affiliations

AstraZeneca (United Kingdom)
GB 2010 - 2010
Bioscience Research
US 2005 - 2005
AstraZeneca (France)
FR 2004 - 2004

External Profiles

OpenAlex Profile Search Semantic Scholar Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now